Titan Pharmaceuticals — Technical Presentation (November 2021)
12 slides from Titan Pharmaceuticals's technical presentation, Nov 9, 2021
Slide 1: Sustained anti-pruritic effect in mice with TP-2021 delivered by subdermal ProNeura Implants
Sustained anti-pruritic effect in mice with TP- 2021, a kappa opioid agonist peptide, delivered by subdermal ProNeura® Implants B. B. Land1, S. Sreedharan2, R. Patel2, T. Beck3, K. DeVarney2, M. Rubin2, *C. Chavkin1; 1Pharmacol., Univ. of Washington, Seattle, WA; 2Titan Pharmaceuticals, South San Fr
Slide 2: Kappa opioid receptor agonists in chronic pruritus
KAPPA OPIOID RECEPTOR AGONISTS IN CHRONIC PRURITUS Nalfurafine Difelikefalin
Slide 3: TP-2021 - A peripheral kappa opioid receptor agonist
TP-2021 - A PERIPHERAL KAPPA OPIOID RECEPTOR AGONIST
Slide 4: TP-2021 binds selectively to kappa opioid receptors
TP-2021 BINDS SELECTIVELY TO KAPPA OPIOID RECEPTORS
Slide 5: Mouse pruritus model
MOUSE PRURITUS MODEL TP-2021 or Difelikefalin Injection (s.c.) 5’GNTI Injection (s.c.) 30 min 20 min Record Scratching Acute Bolus Injection Chronic Subdermal Implantation 5’GNTI Injection (s.c.) 30 min Record Scratching Day 0: Implant or control Days 1, 14, 28, 56: 5’GNTI Challenge
Slide 6: Evaluation of TP-2021 SC bolus in mouse pruritus model
EVALUATION OF TP-2021 SC BOLUS IN MOUSE PRURITUS MODEL 5 10 15 20 25 30 0 5 10 15 Time after injection (m) Scratch Events Scratching Behavior Veh: 5'GNTI 0.05 Veh: Veh Difelikefalin 0.3: 5'GNTI 0.05 TP-2021 0.3: 5'GNTI 0.05 *** *** Veh: Veh Veh: 5'GNTI 0.05 Difelikefalin 0.1: 5'GNTI 0.05 Difelikefal
Slide 7: ProNeura - A long-term drug delivery platform
EVA POLYMER API IMPLANT BLENDED & EXTRUDED PRONEURA - A LONG-TERM DRUG DELIVERY PLATFORM EMA
Slide 8: Low-dose TP-2021 implants in mouse pruritus model
LOW-DOSE TP-2021 IMPLANTS IN MOUSE PRURITUS MODEL 1 14 28 0 50 100 150 Days post implant Scratch Events (% control) 5’ GNTI challenge Placebo/Sham TP-2021 Low Dose 1 implant TP-2021 Low Dose 2 implant
Slide 9: High-dose TP-2021 implants in mouse pruritus model
HIGH-DOSE TP-2021 IMPLANTS IN MOUSE PRURITUS MODEL D28 Control D28 TP-2021 D56 Control D56 TP-2021 0 50 100 150 Scratch Events (% control) * *
Slide 10: Summary
SUMMARY • TP-2021 is a highly selective and potent kappa opioid receptor agonist • TP-2021 shows similar anti-pruritic efficacy and potency to Difelikefalin when delivered by subcutaneous injection • Low dose subdermal TP-2021-ProNeura implants show anti-pruritic efficacy, which diminishes after 2 w
Slide 11: Conclusion
CONCLUSION • TP-2021-ProNeura implants present a viable solution for treatment of chronic pruritus and related conditions for potentially 6 months or longer • A single administration of TP-2021-ProNeura implant could potentially abrogate the need for daily administration, even if a peptide with oral
Slide 12: Contributors
CONTRIBUTORS University of Washington Titan Pharmaceuticals Benjamin Land, Ph.D. Charles Chavkin, Ph.D. Sophia Mar Sunil Sreedharan, Ph.D. Raj Patel, Ph.D. Tyler Beck Kate DeVarney, Ph.D. Marc Rubin, M.D. Funding University of Washington Reagents Titan Pharmaceuticals
Titan Pharmaceuticals — Technical Presentation (November 2021) on 6ix